Mike Hamill joined Flagship Pioneering in 2021 as a senior principal focusing on company creation as part of the origination team led by Avak Kahvejian. In this role, Mike works as part of a team of entrepreneurial scientists exploring innovative ideas, developing the science, intellectual property, and business strategy that form the foundation of breakthrough startups and providing operational leadership through their early stages.
Prior to Flagship, Mike was VP and Head of Research at Axcella Therapeutics, a clinical-stage Flagship Pioneering company developing a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions. He joined Axcella in 2011 as part of the founding scientific team and gained experience across R&D while assuming positions of increasing responsibility and leadership, including leading the platform breakthrough into its current paradigm and IPO in 2019. During his tenure at Axcella, Mike led the conception and design of multiple novel assets, two of which advanced to late-stage therapeutic development. He is also author on several published scientific articles foundational to the Axcella platform and an inventor on over a dozen granted patents.
Prior to Axcella, Mike gained diverse technical experience including structural biology at MIT, analytical sciences at Virdante Pharmaceuticals, and synthetic chemistry at Scynexis.
Mike holds a Ph.D. in Biochemistry from Boston University and a B.Sc. in Chemistry from Gettysburg College.